CANTEL MED CORP (CMN) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of CANTEL MED CORP (CMN) from OUTPERFORM to NEUTRAL on August 14, 2012, with a target price of $30.10.

Cantel Medical Corp. is a healthcare company concentrating primarily in infection prevention and control products and diagnostic and therapeutic medical equipment. Through its United States subsidiary, MediVators, Inc., Cantel serves customers worldwide by designing, developing, manufacturing, marketing and distributing innovative products for the infection prevention and control industry.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on CANTEL MED CORP (CMN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .